重组牛碱性成纤维细胞生长因子治疗膜性结膜炎效果分析.docVIP

重组牛碱性成纤维细胞生长因子治疗膜性结膜炎效果分析 　　[摘要] 目的 探讨重组牛碱性成纤维细胞生长因子治疗膜性结膜炎的效果，为临床提供参考依据。 方法 选择我院2013年2月10日～2014年2月10日收治的膜性结膜炎患者100例作为研究对象，分为实验组和对照组各50例。对照组采取妥布霉素滴眼液、利巴韦林滴眼液治疗，实验组在对照组治疗的基础上加用贝复舒，并在治疗结束后，对比分析两组的治愈率和治愈时间。 结果 实验组和对照组的治愈率分别为96.00%和80.00%（P0.05）；实验组的治愈时间低于对照组（P0.05）；实验组的临床症状缓解时间低于对照组，差异具有统计学意义（P0.05）。结论 在常规治疗的基础上使用贝复舒治疗膜性结膜炎具有显著的疗效，能有效改善患者的临床症状，提高患者的治愈率，缩短患者的治愈时间。 　　[关键词] 贝复舒；膜性结膜炎；妥布霉素滴眼液；利巴韦林滴眼液 　　[中图分类号] R777.31 [文献标识码] B [文章编号] 1673-9701（2016）15-0049-03 　　[Abstract] Objective To analyze and discuss the effect of recombined bovine basic fibroblast growth factor in treatment of membranous conjunctivitis and to provide reference for clinical practice. Methods 100 patients with membranous conjunctivitis treated in our hospital from February 10th， 2013 to February 10th， 2014 were selected and equally divided into study group and control group. Patients in the control group were treated by tobramycin eye drops and ribavirin eye drops， while patients in the study group were additionally given Beifushu（basic fibroblast growth factor）. The cure rate and cure time were compared between two groups after treatment. Results The cure rates of the study group and the control group were 96.00% and 80.00%， respectively（P0.05）. The cure time was significantly shorter in the study group than in the control group （P0.05）. The remission time of clinical symptoms was significantly shorter in the study group than in the control group（P0.05）. Conclusion Addition of Beifushu to conventional therapy has significant efficacy in treatment of membranous conjunctivitis， which can effectively relieve clinical symptoms， increase cure rate， and shorten cure time. Therefore， Beifushu has significant curative effect in treatment of membranous conjunctivitis. 　　[Key words] Beifushu； Membranous conjunctivitis； Tobramycin eye drops； Ribavirin eye drops 　　结膜炎是临床危害性较大的眼科，膜性结膜炎的病情相对较重，患者常伴随着眼睑红肿、疼痛、发热、耳前淋巴结肿大等临床症状，目前治疗该疾病的主要手段是药物治疗，贝复舒是治疗结膜炎的常见药物，自应用以来受到了临床的一致好评。本研究为进一步探究贝复舒应用于膜性结膜炎治疗的效果，特选择了我院收治的10